-
Zelensky slams his security services for 'unacceptable' shootout
-
Looming far-right win in Germany sparks security worries
-
Farage's Reform UK meets as new donation scandal hits
-
Tanker captain arrested over cargo ship sinking off Istanbul
-
Volunteers fight uphill battle against Indonesian fires
-
India hopes 'unique idea' will save athletes from cabin fever
-
PU Prime Launches Australian Operations under ASIC Licence
-
UK asserts 'unshakeable' Falklands commitment after Milei presses claim
-
Night-owl Zverev goes distance to advance as upsets rock US Open
-
How a Dostoevsky novella took TikTok by storm
-
Marathon man Zverev goes distance again to reach US Open third round
-
Zverev goes the distance again to reach US Open third round
-
US study tests psilocybin to fight cancer side effects
-
German AfD's love for Simson mopeds dismays Jewish family behind brand
-
Italy's Meloni throws party to celebrate record in power
-
Two trapped tunnel workers rescued in Nepal 'miracle'
-
After heatwaves, will EU pivot back to the climate fight?
-
Ex-Pakistan coach Gillespie tells Javed 'look in the mirror' over sackings
-
South Korean football referee faces hearing over 'period' insult
-
Monfils falls to Tien in US Open in Grand Slam farewell
-
Toulouse eye Top 14 history after 'difficult' summer
-
Arsenal brace for Chelsea test as Spurs seek spark
-
Springboks and All Blacks seek series lead after war of words
-
Efficient Rybakina reaches US Open third round
-
Bundesliga brings the band back together in Premier League's shadow
-
Taiwan boxer Lin considered 'graceful exit' after Paris Games gold
-
Asian stocks rally as traders pare rate bets ahead of jobs data
-
'I miss my home': Cambodians displaced by conflict start over
-
War-bruised Myanmar finds relief in bareknuckle bloodsport
-
Ailing Auger-Aliassime falls at US Open as Swiatek, Osaka and Gauff advance
-
Gauff downs Badosa to reach US Open third round
-
Tesla launches self-driving 'Cybercab' in Texas
-
New Zealand approves use of party drug MDMA to treat trauma
-
'Wallace & Gromit' creators turn 50 with spook-tacular Shaun yarn
-
Westerners test their mettle at World Nomad Games in Kyrgyzstan
-
New York's Muslims reclaim their city after 9/11 backlash
-
Gauff cruises into US Open third round
-
Premier League transfer windfall a lifeline for ailing French clubs
-
Kyrgios gets month ban for cocaine, enters treatment programme
-
Chile protesters see shades of Pinochet in new security plan
-
AELF Expands Global Commercial Team
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 04
-
Colombian judge bans strikes on guerrillas if minors are present
-
Carreras reverts to fullback as Argentina change four for Australia Test
-
Khachanov shocks ailing Auger-Aliassime, Swiatek and Osaka advance at US Open
-
Wilson back to lead Australia as Kiss rotates team for Argentina
-
Lone juror blocking verdict in US mother's child murder trial: defense
-
Yen surges on new intervention talk, US stocks rally
-
'Kinda chic' - Williams sisters set to launch US Open doubles bid
-
Japan's Ueda fires Lille top of Ligue 1 on debut
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
D.Moore--AMWN